‘Breakthrough’ drugs included on Roche’s list of PhII/III studies axed in Q1 — with pivotal Mirros trial on the chopping block
If you dig into the small print on Roche’s Q1 report out Wednesday, you’ll find several high profile mid- and late-stage setbacks for its experimental drugs in the pipeline.
First up is RG7388 idasanutlin, where Roche noted that its 440-patient Phase III in relapsed and refractory AML — dubbed Mirros — failed the primary endpoint. The trial of the MDM2 inhibitor was axed from the pipeline tracker, along with a Phase II for polycythemia vera, which was termed a pipeline prioritization decision.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 86,400+ biopharma pros reading Endpoints daily — and it's free.